Metastatic non-oat-cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP)
J. D. Bitran, R. K. Desser, T. DeMeester and H. M. Golomb
Fifty-four patients with metastatic non-oat-cell bronchogenic carcinoma
were treated with cyclophosphamide, doxorubicin hydrochloride (Adriamycin),
methotrexate, and procarbazine hydrochloride (CAMP). Eighteen of 51 of
these patients with measurable disease showed an objective response to CAMP
chemotherapy, with a median survival of 12.6 months. Eight of the 18
patients are still alive, and two have been in continuous remission for 20
and 26 months. Survival for patients with stable disease was 12 months,
similar to that for patients demonstrating objective regression in response
to CAMP treatment. Weight loss, performance status, and dominant site of
metastases proved to be important prognostic factors. The CAMP regimen was
well tolerated; there were only two drug-related deaths, both secondary to
infectious complications.
